Whitehawk Therapeutics (WHWK) EBITDA (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of EBITDA data on file, last reported at -$22.3 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$22.3 million, down 130.59% year-over-year; the trailing twelve-month figure through Mar 2026 was -$115.8 million (down 519.3% YoY), and the FY2025 annual result was -$20.5 million, up 67.83% from the prior year.
• EBITDA grew to -$22.3 million in Q1 2026 per WHWK's latest filing, from -$23.3 million in the prior quarter.
• Over five years, EBITDA peaked at $73.0 million in Q1 2025 and troughed at -$52.6 million in Q2 2025.
• A 5-year average of -$13.7 million and a median of -$16.3 million in 2023 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2025: EBITDA plunged 371.46% in 2022, then jumped 498.39% in 2025.
• A 5-year view of EBITDA shows it stood at -$13.9 million in 2022, then retreated by 16.49% to -$16.2 million in 2023, then declined by 12.76% to -$18.3 million in 2024, then declined by 27.19% to -$23.3 million in 2025, then advanced by 4.04% to -$22.3 million in 2026.
• Business Quant data shows WHWK's EBITDA at -$22.3 million in Q1 2026, -$23.3 million in Q4 2025, and -$17.6 million in Q3 2025.